https://allsci.com/news/clinical-trials/paxalisib-triple-negative-breast-cancer/ AllScien 2026-08-28T08:09:20.713343Z Kazia touts 100% clinical benefit rate for paxalisib in early-stage TNBC study https://allsci.com/news/licensing-and-partnerships/combination-flu-vaccine-osivax-pairs-phase-ii/ AllScien 2026-08-28T07:56:31.860607Z Osivax pairs Phase II flu vaccine with GC Biopharma's marketed shot in combination deal https://allsci.com/news/regulatory/fda-approves-covid-19-vaccines-2026-modernas/ AllScien 2026-08-28T07:46:45.320373Z FDA approves Moderna's updated 2026-2027 COVID-19 vaccines for high-risk and older adults https://allsci.com/news/licensing-and-partnerships/genentech-dualitybio-adc-collaboration-taps/ AllScien 2026-08-28T07:39:44.492166Z Genentech taps DualityBio's DUPAC platform for multi-program ADC collaboration https://allsci.com/news/research/shingles-vaccine-cardiovascular-risk-recombinant/ AllScien 2026-08-28T07:33:36.695576Z Shingrix shows potential cardiovascular benefit in US natural experiment https://allsci.com/news/regulatory/skyrizi-crohns-disease-ema-abbvie-seeks-approval/ AllScien 2026-08-27T12:34:22.863778Z AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn's disease https://allsci.com/news/clinical-trials/tezspire-eosinophilic-esophagitis-extends-tslp/ AllScien 2026-08-27T11:56:34.451842Z Amgen/AZ's Tezspire extends TSLP platform to eosinophilic esophagitis with Phase III win https://allsci.com/news/clinical-trials/gv101-rock2-inhibitor-chronic-graft-versus-host-disease/ AllScien 2026-08-26T16:40:07.284481Z Graviton/Beijing Tide’s GV101 posts 86% response rate in Phase Ib cGvHD study https://allsci.com/news/first-in-human-trials/tnfr2-agonist-atopic-dermatitis-trexbio-advances/ AllScien 2026-08-26T16:30:49.163920Z TRexBio’s TNFR2 agonist shows human proof-of-mechanism in Phase I https://allsci.com/news/approvals/pancreatic-cancer-treatment-fda-approval/ AllScien 2026-08-26T16:21:50.215360Z Revolution lands first approval for RAS(ON) platform with Rasonque https://allsci.com/news/regulatory/revtorpyk-pik3ca-breast-cancer-celcuity-seeks/ AllScien 2026-08-26T14:39:57.122167Z Celcuity seeks to expand Revtorpyk label to PIK3CA-mutant breast cancer after beating alpelisib https://allsci.com/news/regulatory/ck0803-fda-fast-track-als-cellenkoss-treg-cell/ AllScien 2026-08-26T14:32:26.133201Z Cellenkos's Treg cell therapy CK0803 wins FDA fast track for ALS https://allsci.com/news/approvals/rett-syndrome-treatment-european-commission/ AllScien 2026-08-26T14:28:02.967034Z EC approves Acadia's Daybu as first-ever Rett syndrome treatment in the EU https://allsci.com/news/first-in-human-trials/mwn110-obesity-trial-shanghai-minwei-launches/ AllScien 2026-08-26T13:14:26.695221Z Shanghai Minwei launches first human trial of ActRIIA/B antibody for obesity https://allsci.com/news/regulatory/pd-1il-15-fusion-protein-colorectal-cancer/ AllScien 2026-08-26T13:08:56.727841Z CSPC's PD-1/IL-15 fusion protein earns FDA Fast Track status for MSS/pMMR CRC https://allsci.com/news/approvals/orzeyful-narcolepsy-approval-takedas-becomes/ AllScien 2026-08-26T13:04:05.657983Z Takeda adds Japan approval for narcolepsy treatment Orzeyful https://allsci.com/news/approvals/trodelvy-pembrolizumab-tnbc-approval-ec-approves/ AllScien 2026-08-26T13:00:47.125670Z Trodelvy stakes out broader first-line TNBC role with EU combo approval https://allsci.com/news/clinical-trials/datroway-phase-iii-urothelial-cancer-plus/ AllScien 2026-08-26T12:27:43.157081Z AZ, Daiichi Sankyo take Datroway-rilvegostomig combo into Phase III bladder cancer trial